Agomelatine, a Melatonin-Derived Drug, as a New Strategy for the Treatment of Colorectal Cancer
暂无分享,去创建一个
Jose D Puentes-Pardo | Sara Moreno-SanJuan | Á. Carazo | J. León | J. Casado | J. Arnedo | Huda Khaldy | Jose D. Puentes-Pardo | Julia Escudero-Feliu
[1] N. Mahmoud,et al. Agomelatine improves streptozotocin-induced diabetic nephropathy through melatonin receptors/SIRT1 signaling pathway. , 2022, International immunopharmacology.
[2] K. Yang,et al. Melatonin and melatonergic drugs in sleep disorders , 2022, Translational and clinical pharmacology.
[3] E. A. de Almeida,et al. Influence of Melatonin Treatment on Cellular Mechanisms of Redox Adaptation in K562 Erythroleukemic Cells , 2022, Genes.
[4] X. Chang,et al. The application of antidepressant drugs in cancer treatment. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[5] Manuel Calderón Sánchez,et al. The melatonergic agonist agomelatine ameliorates high fat diet-induced obesity in mice through the modulation of the gut microbiome. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[6] A. Majumdar,et al. Crosstalk between Sirtuins and Nrf2: SIRT1 activators as emerging treatment for diabetic neuropathy , 2022, Metabolic Brain Disease.
[7] Yool Lee. Roles of circadian clocks in cancer pathogenesis and treatment , 2021, Experimental & Molecular Medicine.
[8] M. Shakibaei,et al. Metabolic Anti-Cancer Effects of Melatonin: Clinically Relevant Prospects , 2021, Cancers.
[9] A. Mahmoud,et al. Agomelatine prevents gentamicin nephrotoxicity by attenuating oxidative stress and TLR-4 signaling, and upregulating PPARγ and SIRT1. , 2021, Life Science.
[10] D. Cardinali,et al. Sirtuins and the circadian clock interplay in cardioprotection: focus on sirtuin 1 , 2021, Cellular and Molecular Life Sciences.
[11] Jose D Puentes-Pardo,et al. Circadian Genes as Therapeutic Targets in Pancreatic Cancer , 2020, Frontiers in Endocrinology.
[12] J. Squire,et al. The Dual Role of Serotonin in Colorectal Cancer , 2020, Trends in Endocrinology & Metabolism.
[13] Jing-Yuan Fang,et al. Comprehensive review of targeted therapy for colorectal cancer , 2020, Signal Transduction and Targeted Therapy.
[14] A. B. Reddy,et al. Circadian rhythms in the absence of the clock gene Bmal1 , 2020, Science.
[15] T. Buchler,et al. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. , 2019, Pharmacology & therapeutics.
[16] Hanchen Xu,et al. Drug resistance and new therapies in colorectal cancer , 2018, World journal of gastroenterology.
[17] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[18] Jian-Hua Luo,et al. Melatonin induces the apoptosis and inhibits the proliferation of human gastric cancer cells via blockade of the AKT/MDM2 pathway. , 2018, Oncology reports.
[19] Ping Li,et al. Tanshindiol C inhibits oxidized low-density lipoprotein induced macrophage foam cell formation via a peroxiredoxin 1 dependent pathway. , 2018, Biochimica et biophysica acta. Molecular basis of disease.
[20] D. Tuveson,et al. Transcriptional Regulation by Nrf2 , 2017, Antioxidants & redox signaling.
[21] Y. Wang,et al. Melatonin inhibits colon cancer RKO cell migration by downregulating Rho-associated protein kinase expression via the p38/MAPK signaling pathway , 2017, Molecular medicine reports.
[22] M. Núñez,et al. AA-NAT, MT1 and MT2 Correlates with Cancer Stem-Like Cell Markers in Colorectal Cancer: Study of the Influence of Stage and p53 Status of Tumors , 2017, International journal of molecular sciences.
[23] R. Reiter,et al. Melatonin and sirtuins: A “not‐so unexpected” relationship , 2017, Journal of pineal research.
[24] F. Artacho-Cordón,et al. Circadian Regulation of Colon Cancer Stem Cells: Implications for Therapy , 2016 .
[25] B. Tang. Sirt1 and the Mitochondria , 2016, Molecules and cells.
[26] M. Dubocovich,et al. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. , 2016, Annual review of pharmacology and toxicology.
[27] R. Kleszcz,et al. Targeting aberrant cancer metabolism — The role of sirtuins , 2015, Pharmacological reports : PR.
[28] S. Hill,et al. Melatonin: an inhibitor of breast cancer. , 2015, Endocrine-related cancer.
[29] R. Kast. Agomelatine or ramelteon as treatment adjuncts in glioblastoma and other M1- or M2-expressing cancers , 2015, Contemporary oncology.
[30] Wei He,et al. Melatonin induces apoptosis of colorectal cancer cells through HDAC4 nuclear import mediated by CaMKII inactivation , 2015, Journal of pineal research.
[31] R. Coppari,et al. SIRT1 Relays Nutritional Inputs to the Circadian Clock Through the Sf1 Neurons of the Ventromedial Hypothalamus. , 2015, Endocrinology.
[32] M. Millan,et al. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties , 2014, British journal of pharmacology.
[33] A B Reddy,et al. Molecular mechanisms of the circadian clockwork in mammals , 2014, FEBS letters.
[34] J. Salmerón,et al. Melatonin reduces endothelin‐1 expression and secretion in colon cancer cells through the inactivation of FoxO‐1 and NF‐κβ , 2014, Journal of pineal research.
[35] H. Stopper,et al. Antidepressant fluoxetine and its potential against colon tumors. , 2014, World journal of gastrointestinal oncology.
[36] Takao Miki,et al. p53 Regulates Period2 Expression and the Circadian Clock , 2013, Nature Communications.
[37] S. Gaetani,et al. Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats. , 2013, The international journal of neuropsychopharmacology.
[38] M. Popoli,et al. Synergistic mechanisms involved in the antidepressant effects of agomelatine , 2012, European Neuropsychopharmacology.
[39] R. Quiles,et al. Gender‐related invasion differences associated with mRNA expression levels of melatonin membrane receptors in colorectal cancer , 2012, Molecular carcinogenesis.
[40] P. Muti,et al. Melatonin triggers p53Ser phosphorylation and prevents DNA damage accumulation , 2012, Oncogene.
[41] Andrew J. Millar,et al. Peroxiredoxins are conserved markers of circadian rhythms , 2012, Nature.
[42] D. Zanette,et al. The melatonin action on stromal stem cells within pericryptal area in colon cancer model under constant light. , 2011, Biochemical and biophysical research communications.
[43] M. Millan,et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development , 2010, Nature Reviews Drug Discovery.
[44] Nihal Ahmad,et al. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer , 2010, Journal of pineal research.
[45] P. Sassone-Corsi,et al. Circadian Control of the NAD+ Salvage Pathway by CLOCK-SIRT1 , 2009, Science.
[46] Florian Kreppel,et al. SIRT1 Regulates Circadian Clock Gene Expression through PER2 Deacetylation , 2008, Cell.
[47] Paolo Sassone-Corsi,et al. The NAD+-Dependent Deacetylase SIRT1 Modulates CLOCK-Mediated Chromatin Remodeling and Circadian Control , 2008, Cell.
[48] M. Dai,et al. 5-Fluorouracil Activation of p53 Involves an MDM2-Ribosomal Protein Interaction* , 2007, Journal of Biological Chemistry.
[49] C. Ip,et al. Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology. , 2007, Cancer research.
[50] D. Mikhailidis,et al. The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation , 2006, BJU international.
[51] R. Labianca,et al. Targeted therapy in colorectal cancer: do we know enough? , 2005, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[52] P. Johnston,et al. 5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.
[53] A. Carrillo-Vico,et al. Expression of melatonin MT(1) and MT(2) receptors, and ROR alpha(1) receptor in transplantable murine Colon 38 cancer. , 2002, Neuro endocrinology letters.
[54] T. Lesuffleur,et al. Resistance of colon cancer cells to long‐term 5‐fluorouracil exposure is correlated to the relative level of Bcl‐2 and Bcl‐XL in addition to Bax and p53 status , 2002, International journal of cancer.
[55] K. Kinzler,et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. , 1999, The Journal of clinical investigation.
[56] F. Kelleher,et al. Circadian molecular clocks and cancer. , 2014, Cancer letters.
[57] P. Sassone-Corsi,et al. The time of metabolism: NAD+, SIRT1, and the circadian clock. , 2011, Cold Spring Harbor symposia on quantitative biology.
[58] M. Pawlikowski,et al. Luzindole but not 4-phenyl-2- propionamidotetralin (4P-PDOT) diminishes the inhibitory effect of melatonin on murine Colon 38 cancer growth in vitro. , 2009, Neuro endocrinology letters.
[59] R. Refinetti. Non-parametric procedures for the determination of phase markers of circadian rhythms. , 1992, International journal of bio-medical computing.